![\"\"](\"https:\/\/www.merckvaccines.com\/mmr\/wp-content\/uploads\/sites\/155\/2025\/12\/8.0-FAQ_MMRII_Banner_1128px_v2-1_910f59.svg?w=1488\")
<\/picture>Frequently asked questions about M-M-R\u00ae<\/sup>II<\/sub><\/span><\/strong>\u00a0(Measles, Mumps, and Rubella Virus Vaccine Live)<\/strong><\/h1><\/p>
<\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n\n\n\n\n<\/div>\n\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What is M-M-R\u00aeII<\/sub>?<\/h4><\/summary>\n<\/div>\n\n\n\nM-M-R\u00ae<\/sup>II<\/sub><\/span> <\/sub>is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.<\/p>\n\n\n\nThe first dose of M-M-R\u00ae<\/sup>II<\/sub><\/span> <\/sub>is administered at 12 to 15 months of age and the second dose of M-M-R\u00ae<\/sup>II<\/sub><\/span> <\/sub>is administered at 4 to 6 years of age.<\/p>\n\n\n\n<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>How long does M-M-R\u00aeII<\/sub> last?<\/h4><\/summary>\n<\/div>\n\n\n\nM-M-R\u00aeII<\/sub> immunization provides coverage that can last 11-13 years after primary vaccination. Based on data from a clinical study<\/a>, neutralizing and ELISA antibodies to MMR viruses were still found 11-13 years after primary vaccination.<\/p>\n\n\n\n<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What is the dosing for M-M-R\u00ae<\/sup>II<\/sub><\/span>?<\/h4><\/summary>\n<\/div>\n\n\n\nThe first dose<\/a><\/span> is administered at 12 to 15 months of age. A second dose<\/a> is administered at 4 to 6 years of age. Approximately 0.5 mL dose is administered either intramuscularly or subcutaneously.<\/p>\n\n\n\n<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What is the Selected Safety Information for M-M-R\u00ae<\/sup>II<\/sub>?<\/h4><\/summary>\n<\/div>\n\n\n\nSelected Safety Information<\/strong><\/p>\n\n\n\n\n- M-M-R\u00ae<\/sup>II<\/sub> is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.<\/li>
- Due caution should be employed in administration of M-M-R\u00ae<\/sup>II<\/sub><\/span> to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.<\/li>
- Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual\u2019s immune status has been evaluated and the individual has been found to be immunocompetent.<\/li>
- Immune globulins (IG) and other blood products should not be given concurrently with M-M-R\u00ae<\/sup>II<\/sub><\/span>. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.<\/li>
- The following adverse reactions have been identified during both the subcutaneous and intramuscular use of M-M-R\u00ae<\/sup>II<\/sub><\/span> or its components in clinical trials or reported during post-approval use: fever, rash, and injection-site reactions.<\/li>
- The following adverse reactions have been identified during the subcutaneous use of M-M-R\u00ae<\/sup>II<\/sub><\/span> or its components in clinical trials or reported during post-approval use: headache, dizziness, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.<\/li><\/ul><\/div>\n\n\n\n<\/div>\n\n\n\n
Dosage and administration<\/strong><\/p>\n\n\n\n<\/div>\n\n\n\n- FOR INTRAMUSCULAR OR SUBCUTANEOUS USE ONLY.<\/em><\/li>
- M-M-R\u00ae<\/sup>II<\/sub> vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R\u00ae<\/sup>II<\/sub><\/span> vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.<\/li><\/ul><\/div>\n\n\n\n<\/div>\n\n\n\n
Before administering M-M-R\u00ae<\/sup>II<\/sub><\/span>, please read the accompanying Prescribing Information<\/a>. The Patient Information<\/a> also is available.<\/strong><\/p>\n\n\n\n<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>When did M-M-R\u00aeII<\/sub> become available for use in the United States?<\/h4><\/summary>\n<\/div>\n\n\n\nM-M-R\u00ae<\/sup>II<\/sub> was initially approved for use in the US in 1978. For over 40 years, it has been an approved vaccine in the US to help prevent infection with measles, mumps, and rubella.<\/p>\n\n\n\n<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>When is M-M-R\u00aeII<\/sub> administered?<\/h4><\/summary>\n<\/div>\n\n\n\nM-M-R\u00aeII<\/sub> is indicated for individuals 12 months and older. View dosing and administration for M-M-R\u00aeII<\/sub><\/a>.<\/p>\n\n\n\n<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>Is M-M-R\u00ae<\/sup>II<\/sub> for adults?<\/h4><\/summary>\n<\/div>\n\n\n\nM-M-R\u00ae<\/sup>II<\/sub> is indicated for individuals 12 months of age and older.<\/p>\n\n\n\n<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>How effective is M-M-R\u00ae<\/sup>II<\/sub><\/span>?<\/h4><\/summary>\n<\/div>\n\n\n\nEfficacy<\/a> of measles, mumps, and rubella vaccines was established in a series of double-blind controlled trials. For additional information, please refer to the Prescribing Information<\/a> for M-M-R\u00ae<\/sup>II<\/sub>.<\/span><\/p>\n\n\n\n<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>How is M-M-R\u00ae<\/sup>II<\/sub><\/span> administered?<\/h4><\/summary>\n<\/div>\n\n\n\n
What is M-M-R\u00aeII<\/sub>?<\/h4><\/summary>\n<\/div>\n\n\n\nM-M-R\u00ae<\/sup>II<\/sub><\/span> <\/sub>is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.<\/p>\n\n\n\nThe first dose of M-M-R\u00ae<\/sup>II<\/sub><\/span> <\/sub>is administered at 12 to 15 months of age and the second dose of M-M-R\u00ae<\/sup>II<\/sub><\/span> <\/sub>is administered at 4 to 6 years of age.<\/p>\n\n\n\n<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>How long does M-M-R\u00aeII<\/sub> last?<\/h4><\/summary>\n<\/div>\n\n\n\nM-M-R\u00aeII<\/sub> immunization provides coverage that can last 11-13 years after primary vaccination. Based on data from a clinical study<\/a>, neutralizing and ELISA antibodies to MMR viruses were still found 11-13 years after primary vaccination.<\/p>\n\n\n\n<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What is the dosing for M-M-R\u00ae<\/sup>II<\/sub><\/span>?<\/h4><\/summary>\n<\/div>\n\n\n\nThe first dose<\/a><\/span> is administered at 12 to 15 months of age. A second dose<\/a> is administered at 4 to 6 years of age. Approximately 0.5 mL dose is administered either intramuscularly or subcutaneously.<\/p>\n\n\n\n<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>What is the Selected Safety Information for M-M-R\u00ae<\/sup>II<\/sub>?<\/h4><\/summary>\n<\/div>\n\n\n\nSelected Safety Information<\/strong><\/p>\n\n\n\n\n- M-M-R\u00ae<\/sup>II<\/sub> is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.<\/li>
- Due caution should be employed in administration of M-M-R\u00ae<\/sup>II<\/sub><\/span> to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.<\/li>
- Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual\u2019s immune status has been evaluated and the individual has been found to be immunocompetent.<\/li>
- Immune globulins (IG) and other blood products should not be given concurrently with M-M-R\u00ae<\/sup>II<\/sub><\/span>. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.<\/li>
- The following adverse reactions have been identified during both the subcutaneous and intramuscular use of M-M-R\u00ae<\/sup>II<\/sub><\/span> or its components in clinical trials or reported during post-approval use: fever, rash, and injection-site reactions.<\/li>
- The following adverse reactions have been identified during the subcutaneous use of M-M-R\u00ae<\/sup>II<\/sub><\/span> or its components in clinical trials or reported during post-approval use: headache, dizziness, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.<\/li><\/ul><\/div>\n\n\n\n<\/div>\n\n\n\n
Dosage and administration<\/strong><\/p>\n\n\n\n<\/div>\n\n\n\n- FOR INTRAMUSCULAR OR SUBCUTANEOUS USE ONLY.<\/em><\/li>
- M-M-R\u00ae<\/sup>II<\/sub> vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R\u00ae<\/sup>II<\/sub><\/span> vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.<\/li><\/ul><\/div>\n\n\n\n<\/div>\n\n\n\n
Before administering M-M-R\u00ae<\/sup>II<\/sub><\/span>, please read the accompanying Prescribing Information<\/a>. The Patient Information<\/a> also is available.<\/strong><\/p>\n\n\n\n<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>When did M-M-R\u00aeII<\/sub> become available for use in the United States?<\/h4><\/summary>\n<\/div>\n\n\n\nM-M-R\u00ae<\/sup>II<\/sub> was initially approved for use in the US in 1978. For over 40 years, it has been an approved vaccine in the US to help prevent infection with measles, mumps, and rubella.<\/p>\n\n\n\n<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>When is M-M-R\u00aeII<\/sub> administered?<\/h4><\/summary>\n<\/div>\n\n\n\nM-M-R\u00aeII<\/sub> is indicated for individuals 12 months and older. View dosing and administration for M-M-R\u00aeII<\/sub><\/a>.<\/p>\n\n\n\n<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>Is M-M-R\u00ae<\/sup>II<\/sub> for adults?<\/h4><\/summary>\n<\/div>\n\n\n\nM-M-R\u00ae<\/sup>II<\/sub> is indicated for individuals 12 months of age and older.<\/p>\n\n\n\n<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>How effective is M-M-R\u00ae<\/sup>II<\/sub><\/span>?<\/h4><\/summary>\n<\/div>\n\n\n\nEfficacy<\/a> of measles, mumps, and rubella vaccines was established in a series of double-blind controlled trials. For additional information, please refer to the Prescribing Information<\/a> for M-M-R\u00ae<\/sup>II<\/sub>.<\/span><\/p>\n\n\n\n<\/div>\n<\/div><\/details><\/div>\n\n\n\ndefault-sum-open-background-color<\/div>default-sum-close-background-color<\/div>false<\/div>default-sum-open-hover-color<\/div>default-sum-open-focus-color<\/div>default-sum-close-focus-color<\/div>.default-sum-close-hover-color<\/div>How is M-M-R\u00ae<\/sup>II<\/sub><\/span> administered?<\/h4><\/summary>\n<\/div>\n\n\n\n
M-M-R\u00ae<\/sup>II<\/sub><\/span> <\/sub>is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.<\/p>\n\n\n\n The first dose of M-M-R\u00ae<\/sup>II<\/sub><\/span> <\/sub>is administered at 12 to 15 months of age and the second dose of M-M-R\u00ae<\/sup>II<\/sub><\/span> <\/sub>is administered at 4 to 6 years of age.<\/p>\n\n\n\n M-M-R\u00aeII<\/sub> immunization provides coverage that can last 11-13 years after primary vaccination. Based on data from a clinical study<\/a>, neutralizing and ELISA antibodies to MMR viruses were still found 11-13 years after primary vaccination.<\/p>\n\n\n\n The first dose<\/a><\/span> is administered at 12 to 15 months of age. A second dose<\/a> is administered at 4 to 6 years of age. Approximately 0.5 mL dose is administered either intramuscularly or subcutaneously.<\/p>\n\n\n\n Selected Safety Information<\/strong><\/p>\n\n\n\n\n Dosage and administration<\/strong><\/p>\n\n\n\n Before administering M-M-R\u00ae<\/sup>II<\/sub><\/span>, please read the accompanying Prescribing Information<\/a>. The Patient Information<\/a> also is available.<\/strong><\/p>\n\n\n\n M-M-R\u00ae<\/sup>II<\/sub> was initially approved for use in the US in 1978. For over 40 years, it has been an approved vaccine in the US to help prevent infection with measles, mumps, and rubella.<\/p>\n\n\n\n M-M-R\u00aeII<\/sub> is indicated for individuals 12 months and older. View dosing and administration for M-M-R\u00aeII<\/sub><\/a>.<\/p>\n\n\n\n M-M-R\u00ae<\/sup>II<\/sub> is indicated for individuals 12 months of age and older.<\/p>\n\n\n\n Efficacy<\/a> of measles, mumps, and rubella vaccines was established in a series of double-blind controlled trials. For additional information, please refer to the Prescribing Information<\/a> for M-M-R\u00ae<\/sup>II<\/sub>.<\/span><\/p>\n\n\n\nHow long does M-M-R\u00aeII<\/sub> last?<\/h4><\/summary>
What is the dosing for M-M-R\u00ae<\/sup>II<\/sub><\/span>?<\/h4><\/summary>
What is the Selected Safety Information for M-M-R\u00ae<\/sup>II<\/sub>?<\/h4><\/summary>
When did M-M-R\u00aeII<\/sub> become available for use in the United States?<\/h4><\/summary>
When is M-M-R\u00aeII<\/sub> administered?<\/h4><\/summary>
Is M-M-R\u00ae<\/sup>II<\/sub> for adults?<\/h4><\/summary>
How effective is M-M-R\u00ae<\/sup>II<\/sub><\/span>?<\/h4><\/summary>
How is M-M-R\u00ae<\/sup>II<\/sub><\/span> administered?<\/h4><\/summary>